GSK has reached agreements to settle lawsuits regarding its Zantac heartburn drug, agreeing to pay $2.3 billion while maintaining it has no liability for the claims.
Despite settling, GSK states the "scientific consensus remains that there is no consistent or reliable evidence" proving that ranitidine, the active ingredient in Zantac, is carcinogenic.
The settlements include $2.2 billion to a coalition of plaintiff firms representing about 80,000 cases, and an additional $70 million to US lab Valisure, pending DOJ approval.
Zantac, known as ranitidine and produced by GSK and other competitors, was flagged by the FDA in 2019 due to low levels of an environmental contaminant.
Collection
[
|
...
]